Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
Submitted by
admin
on April 25, 2016 - 6:39pm
Source:
Yahoo
News Tags:
AbbVie
FDA
Viekira Pak
hepatitis C
Headline:
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
Do Not Allow Advertisers to Use My Personal information